All Stories

Caris Life Sciences boosts IPO price to raise $494M

The cancer testing company claimed a valuation of about $5.9 billion, while selling 23.5 million shares under the Nasdaq ticker "CAI" at $21 apiece.

Jun 18, 2025 - 20:20
 0
Caris Life Sciences boosts IPO price to raise $494M
The cancer testing company claimed a valuation of about $5.9 billion, while selling 23.5 million shares under the Nasdaq ticker "CAI" at $21 apiece.
Read More

Tags:

Previous Article

Zealand Pharma’s GLP-1/GLP-2 candidate linked to 11.6% weight loss after 28 weeks

Next Article

FDA approves twice-yearly shot of Gilead drug for HIV prevention

Related Posts

GSK pays $1.2B upfront for Boston Pharmaceuticals' lead liver disease drug

GSK pays $1.2B upfront for Boston Pharmaceuticals' lead...

May 14, 2025  0

Quest Diagnostics taps MD Anderson for cancer risk blood test

Quest Diagnostics taps MD Anderson for cancer risk bloo...

Jun 10, 2025  0

FDA's 'heavy workload' blamed for delays to KalVista's angioedema drug approval decision

FDA's 'heavy workload' blamed for delays to KalVista's ...

Jun 16, 2025  0